Citations

Clear

2303 citation(s) found for "Yu, Edward".

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
Vermeire, Séverine , D’Haens, Geert , Baert, Filip , Kobayashi, Taku, Loftus, Edward V. , Bhatia, Siddharth , Agboton, Christian , Rosario, Maria , Chen, Chunlin , Zhang, Wenwen , Kisfalvi, Krisztina, Sandborn, William J. , Kobayashi, Taku , Loftus, Edward V , Kobayashi, Taku , Vermeire, Séverine , Danese, Silvio

Mayo Clinic

Journal of Crohn's and Colitis | August 16, 2021 | Volume: 16 | Issue: 1 | Pages: 27-38

10.1093/ecco-jcc/jjab133 | PMID 34402887 Get It

Abstract Background and Aims To report results from VISIBLE 2, a randomised, double-blind, placebo-controlled, phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn’s disease [CD]. Methods Following open-label vedolizumab 300 mg intravenous induction therapy at Weeks 0 and 2, Week 6 clinical responders (≥70-point decrease in CD Activity Index [CDAI] score from baseline) were randomised 2:1 to receive double-blind maintenance vedolizumab 108 mg SC or placebo every 2 weeks until Week 50. Assessments at Week 52 included clinical remission [primary endpoint; CDAI ≤150], enhanced clinical response [≥100-point decrease in CDAI from baseline], corticosteroid-free clinical remission among patients using a corticosteroid at baseline, clinical remission in anti-tumour necrosis factor [anti-TNF]-naïve patients, and safety. Results Following vedolizumab intravenous induction, 275 patients were randomised to vedolizumab SC and 135 to placebo maintenance. At Week 52, 48.0% of patients receiving vedolizumab SC versus 34.3% receiving placebo were in clinical remission [p = 0.008]. Enhanced clinical response at Week 52 was achieved by 52.0% versus 44.8% of patients receiving vedolizumab SC versus placebo, respectively [p = 0.167]. At Week 52, 45.3% and 18.2% of patients receiving vedolizumab SC and placebo, respectively, were in corticosteroid-free clinical remission, and 48.6% of anti-TNF-naïve patients receiving vedolizumab SC and 42.9% receiving placebo were in clinical remission. Injection site reaction was the only new safety finding observed for vedolizumab SC [2.9%]. Conclusions Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy.
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Cheifetz, Adam S. , Afif, Waqqas , Dubinsky, Marla C. , Loftus, Edward V. , Osterman, Mark T. , Saroufim, Ariana, Yarur, Andrés , Melmed, Gil , Papamichael, Konstantinos , Loftus, Edward V , Melmed, Gil Y , Yarur, Andres J , Abreu, María T. , Cross, Raymond K. , Siegel, Corey A

Mayo Clinic

American Journal of Gastroenterology | August 13, 2021 | Volume: 116 | Issue: 10 | Pages: 2014-2025

10.14309/ajg.0000000000001396 | PMID 34388143 Get It

Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to provide a consensus statement regarding the clinical utility of TDM for biologics in inflammatory bowel disease (IBD). A modified Delphi method was applied to develop consensus statements. A comprehensive literature review was performed regarding TDM of biologic therapies in IBD, and 45 statements were subsequently formulated on the potential application of TDM in IBD. The statements, along with literature, were then presented to a panel of 10 gastroenterologists with expertise in IBD and TDM who anonymously rated them on a scale of 1–10 (1 = strongly disagree and 10 = strongly agree). An expert consensus development meeting was held virtually to review, discuss, refine, and reformulate statements that did not meet criteria for agreement or that were ambiguous. During the meeting, additional statements were proposed. Panelists then confidentially revoted, and statements rated ≥7 by 80% or more of the participants were accepted. During the virtual meeting, 8 statements were reworded, 7 new statements were proposed, and 19 statements were rerated. Consensus was finally reached in 48/49 statements. The panel agreed that reactive TDM should be used for all biologics for both primary nonresponse and secondary loss of response. It was recommended that treatment discontinuation should not be considered for infliximab or adalimumab until a drug concentration of at least 10–15 μg/mL was achieved. Consensus was also achieved regarding the utility of proactive TDM for anti–tumor necrosis factor therapy. It was recommended to perform proactive TDM after induction and at least once during maintenance. Consensus was achieved in most cases regarding the utility of TDM of biologics in IBD, specifically for reactive and proactive TDM of anti–tumor necrosis factors.
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
Francini, Edoardo , Ou, Fang‐Shu , Wolfe, Eric, O’Connor, Edward , Gydush, Gregory, Kelleher, Kaitlin M. , Bhatt, Rupal S. , Balk, Steven P. , Sweeney, Christopher J. , Adalsteinsson, Viktor A. , Taplin, Mary‐Ellen , Choudhury, Atish D. , Wolfe, Eric G, Balk, Steven , Choudhury, Atish D , Ou, Fang-Shu , Sweeney, Christopher , Rhoades, Justin , Ha, Gavin

Mayo Clinic

Cancers | August 12, 2021 | Volume: 13 | Issue: 16 | Pages: 4055

10.3390/cancers13164055 | PMID 34439209 Get It

There are no biomarkers predictive of resistance to docetaxel or cabazitaxel validated for patients with metastatic castration-resistant prostate cancer (mCRPC). We assessed the association between ABCB1 amplification and primary resistance to docetaxel or cabazitaxel for patients with mCRPC, using circulating cell-free DNA (cfDNA). Patients with ≥1 plasma sample drawn within 12 months before starting docetaxel (cohort A) or cabazitaxel (cohort B) for mCRPC were identified from the Dana–Farber Cancer Institute IRB approved database. Sparse whole genome sequencing was performed on the selected cfDNA samples and tumor fractions were estimated using the computational tool ichorCNA. We evaluated the association between ABCB1 amplification or other copy number alterations and primary resistance to docetaxel or cabazitaxel. Of the selected 176 patients, 45 samples in cohort A and 21 samples in cohort B had sufficient tumor content. No significant association was found between ABCB1 amplification and primary resistance to docetaxel (p = 0.58; odds ratio (OR) = 1.49) or cabazitaxel (p = 0.97; OR = 1.06). No significant association was found between exploratory biomarkers and primary resistance to docetaxel or cabazitaxel. In this study, ABCB1 amplification did not predict primary resistance to docetaxel or cabazitaxel for mCRPC. Future studies including ABCB1 amplification in a suite of putative biomarkers and a larger cohort may aid in drawing definitive conclusions.
Research Priorities in the Secondary Prevention of Atrial Fibrillation: A National Heart, Lung, and Blood Institute Virtual Workshop Report
Benjamin, Emelia J. , Al‐Khatib, Sana M. , Desvigne‐Nickens, Patrice , Alonso, Álvaro , Djoussé, Luc , Forman, Daniel E. , Gillis, Anne M. , Hendriks, Jeroen , Hills, Mellanie True , Kirchhof, Paulus , Marcus, Gregory M. , Murray, Katherine T. , Parkash, Ratika , Redline, Susan , Rienstra, Michiel , Wang, Paul J. , Cooper, Lawton S. , Go, Alan S. , Alonso, Alvaro , Kirchhof, Paulus , True Hills, Mellanie , Rienstra, Michiel , Benjamin, Emelia J , Hendriks, Jeroen M , Marcus, Gregory M , Forman, Daniel Edward , Link, Mark S. , Mehra, Reena , Piña, Ileana L. , Sanders, Prashanthan , Somers, Virend K. , Wagoner, David R. Van , Al-Khatib, Sana M.

Mayo Clinic

Journal of the American Heart Association | August 5, 2021 | Volume: 10 | Issue: 16 | Pages: No page available

10.1161/jaha.121.021566 | PMID 34351783 Get It

There has been sustained focus on the secondary prevention of coronary heart disease and heart failure; yet, apart from stroke prevention, the evidence base for the secondary prevention of atrial fibrillation (AF) recurrence, AF progression, and AF‐related complications is modest. Although there are multiple observational studies, there are few large, robust, randomized trials providing definitive effective approaches for the secondary prevention of AF. Given the increasing incidence and prevalence of AF nationally and internationally, the AF field needs transformative research and a commitment to evidenced‐based secondary prevention strategies. We report on a National Heart, Lung, and Blood Institute virtual workshop directed at identifying knowledge gaps and research opportunities in the secondary prevention of AF. Once AF has been detected, lifestyle changes and novel models of care delivery may contribute to the prevention of AF recurrence, AF progression, and AF‐related complications. Although benefits seen in small subgroups, cohort studies, and selected randomized trials are impressive, the widespread effectiveness of AF secondary prevention strategies remains unknown, calling for development of scalable interventions suitable for diverse populations and for identification of subpopulations who may particularly benefit from intensive management. We identified critical research questions for 6 topics relevant to the secondary prevention of AF: (1) weight loss; (2) alcohol intake, smoking cessation, and diet; (3) cardiac rehabilitation; (4) approaches to sleep disorders; (5) integrated, team‐based care; and (6) nonanticoagulant pharmacotherapy. Our goal is to stimulate innovative research that will accelerate the generation of the evidence to effectively pursue the secondary prevention of AF.
Thymic stromal lymphopoietin induces adipose loss through sebum hypersecretion
Choa, Ruth , Tohyama, Junichiro , Wada, Shogo , Meng, Hu , Hu, Jian , Okumura, Mariko, May, Rebecca M., Robertson, Tanner F. , Pai, Ruth-Anne Langan , Nace, Arben , Hopkins, Christian , Jacobsen, Elizabeth A. , Haldar, Malay , Behrens, Edward M. , Minn, Andy J. , Seale, Patrick , Cotsarelis, George , Li, Mingyao , Kambayashi, Taku , FitzGerald, Garret A , Behrens, Edward M , Kim, Brian , Seykora, John T , Li, Mingyao , Arany, Zoltan Pierre , Kambayashi, Taku , Jacobsen, Elizabeth A

Mayo Clinic

Science | July 29, 2021 | Volume: 373 | Issue: 6554 | Pages: No page available

10.1126/science.abd2893 | PMID 34326208 Get It

Sweat out the fat with TSLP! Thymic stromal lymphopoietin (TSLP) is a cytokine that can promote immune responses that characterize allergic diseases. Choa et al . found that mice engineered to produce elevated TSLP displayed selective white adipose tissue loss that protected them from obesity, insulin resistance, and steatohepatitis (see the Perspective by Schneider). Protection was not mediated by eosinophils, regulatory T cells, or innate lymphoid cells. Rather, TLSP induced the migration of conventional T cells to sebaceous glands in the skin. Once there, these T cells promoted white adipose tissue loss by the hypersecretion of sebum, a lipid-rich substance that augments the skin’s barrier function. This mechanism, which likely evolved to enhance cutaneous antimicrobial defenses, could be possibly targeted in future treatments for obesity. —STS
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Auclair, Daniel , Adam, Stacey J. , Agarwal, Amit , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica R. , Connors, Dana E. , Dash, Ajeeta B. , Bacco, Alessandra Di , Ling, Du, Flores‐Montero, Juan , Ghobrial, Irene M. , Gormley, Nicole , Gupta, Ira, Higley, Howard R., Hillengaß, Jens , Kanapuru, Bindu , Kazandjian, Dickran , Kelloff, Gary J. , Kremer, Brandon E. , Lightbody, Elizabeth D. , Lomas, Oliver , Mateos, María‐Victoria , de, Rocío Montes , Mukundan, Lata , Munshi, Nikhil C. , O’Donnell, Elizabeth , Paiva, Bruno , Patel, Reshma, Pugh, Trevor J. , Ramasamy, Karthik , Ray, Jill, Roshal, Mikhail , Ross, Jeremy A. , Sigman, Caroline C. , Thoren, Katie , Trudel, Suzanne , Ulaner, Gary A. , Valente, Nancy, Weiss, Brendan M. , Zamagni, Elena , Kumar, Shaji , Adam, Stacey J , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica , Connors, Dana E , Dash, Ajeeta B , Di Bacco, Alessandra , Flores-Montero, Juan , Gay, Francesca , Hillengass, Jens , Landgren, C Ola , Lomas, Oliver C , Montes de Oca, Rocio , Pugh, Trevor J , Ramasamy, Karthik , Sigman, Caroline C , Thoren, Katie L , Paiva, Bruno , Ghobrial, Irene M , Ulaner, Gary , Gormley, Nicole , Anderson, Kenneth C. , Avet‐Loiseau, Hervé , Facon, Thierry T.F. , Gay, Francesca , Kirsch, Ilan R. , Landgren, Ola , Lonial, Sagar , Órfão, Alberto , Patel, Reshma, Zamagni, Elena

Mayo Clinic

Clinical Cancer Research | July 28, 2021 | Volume: 27 | Issue: 19 | Pages: 5195-5212

10.1158/1078-0432.ccr-21-1059 | PMID 34321279 Get It

AbstractThe development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow–based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in patients with multiple myeloma. Complementary liquid biopsy–based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid–based technologies are still developing and will prove important to further our understanding of the biology of MRD. On the regulatory front, multiple retrospective individual patient and clinical trial level meta-analyses have already shown and will continue to assess the potential of MRD as a surrogate for patient outcome. Given all this progress, it is not surprising that a number of clinicians are now considering using MRD to inform real-world clinical care of patients across the spectrum from smoldering myeloma to relapsed refractory multiple myeloma, with each disease setting presenting key challenges and questions that will need to be addressed through clinical trials. The pace of advances in targeted and immune therapies in multiple myeloma is unprecedented, and novel MRD-driven biomarker strategies are essential to accelerate innovative clinical trials leading to regulatory approval of novel treatments and continued improvement in patient outcomes.
Systemic sclerosis portends increased risk of conduction and rhythm abnormalities at diagnosis and during disease course: A US population-based cohort
Radwan, Yasser , Kurmann, Reto , Sandhu, Avneek Singh, El‐Am, Edward , Crowson, Cynthia S. , Matteson, Eric L. , Osborn, Thomas G. , Warrington, Kenneth J , Radwan, Yasser A , Kurmann, Reto D, Sandhu, Avneek S, El-Am, Edward A, Mankad, Rekha , Makol, Ashima , Warrington, Kenneth J.

Mayo Clinic

Journal of Scleroderma and Related Disorders | July 28, 2021 | Volume: 6 | Issue: 3 | Pages: 277-285

10.1177/23971983211034074 | PMID 35295788 Get It

Objectives: To study the incidence, risk factors, and outcomes of conduction and rhythm disorders in a population-based cohort of patients with systemic sclerosis versus nonsystemic sclerosis comparators. Methods: An incident cohort of patients with systemic sclerosis (1980–2016) from Olmsted County, MN, was compared to age- and sex-matched nonsystemic sclerosis subjects (1:2). Electrocardiograms, Holter electrocardiograms, and a need for cardiac interventions were reviewed to determine the occurrence of any conduction or rhythm abnormalities. Results: Seventy-eight incident systemic sclerosis cases and 156 comparators were identified (mean age 56 years, 91% female). The prevalence of any conduction disorder before systemic sclerosis diagnosis compared to nonsystemic sclerosis subjects was 15% versus 7% ( p = 0.06), and any rhythm disorder was 18% versus 13% ( p = 0.33). During a median follow-up of 10.5 years in patients with systemic sclerosis and 13.0 years in nonsystemic sclerosis comparators, conduction disorders developed in 25 patients with systemic sclerosis with cumulative incidence of 20.5% (95% confidence interval: 12.4%–34.1%) versus 28 nonsystemic sclerosis patients with cumulative incidence of 10.4% (95% confidence interval: 6.2%–17.4%) (hazard ratio: 2.57; 95% confidence interval: 1.48–4.45), while rhythm disorders developed in 27 patients with systemic sclerosis with cumulative incidence of 27.3% (95% confidence interval: 17.9%–41.6%) versus 43 nonsystemic sclerosis patients with cumulative incidence of 18.0% (95% confidence interval: 12.3%–26.4%) (hazard ratio: 1.62; 95% confidence interval: 1.00–2.64). Age, pulmonary hypertension, and smoking were identified as risk factors. Conclusion: Patients with systemic sclerosis have an increased risk of conduction and rhythm disorders both at disease onset and over time, compared to nonsystemic sclerosis patients. These findings warrant increased vigilance and screening for electrocardiogram abnormalities in systemic sclerosis patients with pulmonary hypertension.
Structure of an AMPK complex in an inactive, ATP-bound state
Yan, Yan , Mukherjee, Somnath , Harikumar, Kaleeckal G. , Strutzenberg, Timothy S. , Zhou, X. Edward , Suino-Powell, Kelly, Xu, Ting-Hai , Sheldon, Ryan D. , Lamp, Jared , Brunzelle, J.S. , Radziwon, Katarzyna, Novick, Scott J. , Vega, Irving E. , Xu, H. Eric , Griffin, Patrick R. , Kossiakoff, Anthony A. , Melcher, Karsten , Brunzelle, Joseph S , Ellis, Abigail , Novick, Scott J , Jones, Russell G , Miller, Laurence J , Xu, H Eric , Griffin, Patrick R , Melcher, Karsten , Harikumar, Kaleeckal G , Jones, Russell G. , Miller, Laurence J.

Mayo Clinic

Science | July 22, 2021 | Volume: 373 | Issue: 6553 | Pages: 413-419

10.1126/science.abe7565 | PMID 34437114 Get It

How to catch a dynamic state AMP-activated protein kinase (AMPK) is a key sensor of energy status in eukaryotes. Its dynamic structure is regulated by allosteric factors including phosphorylation and binding of nucleotides and metabolites. Yan et al. developed conformation-specific antibodies that trap AMPK in a fully inactive state that has experienced a large, domain-level rotation. Biophysical experiments in cells and in vitro are consistent with the structural work and support a model in which the activation loop is fully exposed in the completely inactive, dephosphorylated state. These structures inform our understanding of the complex allosteric behavior in this crucial metabolic regulator. Science , abe7565, this issue p. 413
HER-2 Neu gene: A valuable therapeutic target in metastatic mucoepidermoid carcinoma
Mohammed, Turab , Mangeshkar, Shaunak , Desai, Aakash , Hegde, Upendra P. , Desai, Aakash P

Mayo Clinic

Journal of Oncology Pharmacy Practice | July 13, 2021 | Volume: 27 | Issue: 7 | Pages: 1806-1809

10.1177/10781552211032722 | PMID 34255585 Get It

Introduction Salivary gland neoplasms (SGNs) respond poorly to the traditional chemotherapy agents limiting the availability of systemic treatment options in the metastatic setting. The recent identification of actionable molecular targets in SGNs has led to the evaluation of targeted therapies in non-approved advanced SGNs. Case Report We present the case of an elderly male with HER-2 Neu overexpressing metastatic mucoepidermoid carcinoma (MEC) who demonstrated a prompt and sustained disease response to targeted therapies directed against HER-2 Neu with long survival interrupted by hepatoxicity to Trastuzumab emtansine (TDM-1) treatment. Management and Outcome: The patient was started on Trastuzumab and Pertuzumab on a clinical trial and resulted in an objective improvement sustained over 3 years. Following the disease progression, TDM-1 was started with a response until the patient developed severe hepatotoxicity as an adverse effect of TDM-1 therapy resulting in its discontinuation. Close follow-up post-treatment-discontinuation demonstrated continued clinical improvement until 6 months, when the patient developed brain metastasis. He passed away a few months later in hospice care. Discussion The metastatic MEC in our patient overexpressed HER-2 Neu. Owing to Trastuzumab and Pertuzumab response, Trastuzumab emtansine (TDM-1) was initiated on a compassionate basis which further extended the survival but had to be terminated owing to adverse effects. Given the paucity of data on targeted therapies in the treatment of metastatic SGNs and the safety, tolerability, and efficacy of TDM-1 therapy among the elderly, further studies are warranted to answer these important questions and to identify eligible patients for this novel treatment option.